HCPLive

JUNE 29, 2024

Patients with RA and obesity exhibited worse scores for subjective measures like pain and fatigue compared to those without obesity.

Obesity 98

Obesity Outcomes 98

Med Page Today

JULY 5, 2024

(MedPage Today) -- GLP-1 receptor agonists lowered the risk of several obesity-associated cancers, a retrospective analysis of electronic health records suggested. Compared with insulin, GLP-1s were associated with a lower risk for developing.

Obesity 112

Obesity Cancer Diabetes 112

American Heart News - Heart News

MAY 20, 2024

Statement Highlights: More than 40% of adults in the United States live with obesity, and the percentage of people living with obesity continues to increase dramatically. While experts have learned a great deal about the causes of obesity and.

Obesity 94

Obesity 94

Med Page Today

SEPTEMBER 10, 2024

(MedPage Today) -- Liraglutide (Saxenda) added to lifestyle intervention helped reduce BMI in young children with obesity, the phase IIIa SCALE Kids trial found. By week 56, kids, ages 6 to <12 years, on once-daily 3-mg liraglutide lost 5.8.

BMI 86

BMI Obesity 86

HCPLive

APRIL 19, 2024

This interview segment featured a discussion on Jay’s ACP Internal Medicine Meeting presentation ‘Advancing Equitable Approaches to Improve Obesity Care.’

Obesity 119

Obesity 119

HCPLive

JANUARY 25, 2024

After adjusting for confounders, data revealed higher levels of obesity indices were linked with a gradual and dose-dependent increase in urate levels.

Obesity 115

Obesity 115

American College of Cardiology

SEPTEMBER 11, 2024

The following are key points to remember from a European Society of Cardiology (ESC) clinical consensus statement on obesity and cardiovascular disease (CVD).

Obesity 70

Obesity Cardiovascular Disease Article 70

Heart BMJ

SEPTEMBER 16, 2024

Obesity is a major global health issue and a leading cause of premature death. The prevalence of obesity has been rising faster than most other known modifiable risk factors. In a Global Burden of Disease analysis, the prevalence of obesity was found to have doubled in more than 70 countries from 1980 to 2013.

Obesity 52

Obesity Blood Pressure BMI Risk Factors 52

Medical Xpress - Cardiology

JULY 9, 2024

Researchers from King's have identified evidence to suggest that lifestyle changes could offset the risk of some adult heart disorders that result from maternal obesity and changes in fetal heart development.

Obesity 93

Obesity Diet Exercise Research 93

Med Page Today

APRIL 18, 2024

(MedPage Today) -- Tirzepatide (Zepbound) injections reduced sleep apnea severity among patients with obesity, regardless of positive airway pressure (PAP) use, according to topline data from two phase III trials. In the SURMOUNT-OSA 1 study.

Obesity 102

Obesity 102

Cardiometabolic Health Congress

JANUARY 3, 2024

In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.

Obesity 97

Obesity Diabetes Blood Pressure BMI 97

HCPLive

FEBRUARY 2, 2024

Obesity was linked to an increased risk of focal segmental glomerulosclerosis and hypertensive nephropathy, with further analysis revealing its impact on the risk of developing end-stage kidney disease.

Kidney Disease 105

Kidney Disease Obesity Hypertension 105

CardiacWire

AUGUST 14, 2024

Rivus Pharmaceuticals’ HU6 is showing promise as a future obesity-related HFpEF treatment, after topline results from its Phase 2a HuMAIN trial revealed valuable weight, symptom, and cardiometabolic improvements – without the risk of muscle loss. The post Rivus HU6 Shows Obesity-HFpEF Potential appeared first on Cardiac Wire.

Obesity 52

Obesity Diet Quality of Life Blood Pressure 52

The British Journal of Cardiology

OCTOBER 8, 2024

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering and weight-lowering agents used in the management of type 2 diabetes mellitus and obesity.

Obesity 52

Obesity Diabetes Kidney Disease Heart Failure 52

American Heart News - Heart News

SEPTEMBER 5, 2024

Research Highlights: In an analysis of 18 randomized clinical trials, people with obesity and high blood pressure who underwent bariatric (weight-loss) surgery were almost three times more likely to achieve blood pressure remission, defined as.

Blood Pressure 77

Blood Pressure Obesity Research 77

HCPLive

FEBRUARY 5, 2024

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

Blood Pressure 116

Blood Pressure Obesity Diabetes 116

Heart BMJ

SEPTEMBER 25, 2024

Background The relationships between various obesity measures and hypertensive disorders of pregnancy (HDP) remain inadequately explored, and their causal links are not well understood. to 2.15; obesity: OR=3.77, 95% CI 3.45 to 1.90; obesity: OR=3.46, 95% CI 3.16 to 2.15; obesity: OR=3.77, 95% CI 3.45

Obesity 52

Obesity Hypertension Public Health 52

HCPLive

JUNE 23, 2024

In the special on-site ADA 2024 episode, hosts are joined by the ADA's Chief Scientific and Medical Officer Robert Gabbay, MD, PhD, to discuss the newly formed Obesity Association.

Obesity 83

Obesity Diabetes 83

HCPLive

FEBRUARY 14, 2024

Patients with ACPA-positive RA and obesity had greater DAS44 scores compared to normal-weight patients, although this difference was not present in ACPA-negative RA.

Obesity 105

Obesity 105

HCPLive

AUGUST 1, 2024

Eli Lilly's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity in the phase 3 SUMMIT trial.

Heart Failure 69

Heart Failure Obesity Outcomes 69

HCPLive

JUNE 21, 2024

In retrospective, observational research at ADA 2024, real-world weight loss was linked to a reduction in the risk of obesity-related cancers.

Obesity 80

Obesity Cancer Research 80

Cardiovascular Diabetology

SEPTEMBER 15, 2024

Background Heart failure (HF) is a serious and common condition affecting millions of people worldwide, with obesity being a major cause of metabolic disorders such as diabetes and cardiovascular disease. Conclusions The findings suggest that fenofibrate may be a useful therapeutic agent for obesity- and diabetes-related cardiomyopathy.

Obesity 52

Obesity Heart Failure Diabetes Cardiomyopathy 52

Circulation

MAY 20, 2024

Obesity is a recognized public health epidemic with a prevalence that continues to increase dramatically in nearly all populations, impeding progress in reducing incidence rates of cardiovascular disease. Circulation, Ahead of Print.

Obesity 78

Obesity Public Health Research Cardiovascular Disease 78

American Heart News - Heart News

FEBRUARY 5, 2024

Research Highlights: The weight loss medication tirzepatide significantly lowered the systolic blood pressure of nearly 500 adults who had obesity and took the medication for 36 weeks, or about eight months, in a subset of an international clinical.

Blood Pressure 112

Blood Pressure Obesity Research 112

Journal of Clinical Investigation - Cardiology

FEBRUARY 1, 2024

Nonalcoholic fatty liver disease (NAFLD) is prevalent in the majority of individuals with obesity, but in a subset of these individuals, it progresses to nonalcoholic steatohepatitis (0NASH) and fibrosis. The mechanisms that prevent NASH and fibrosis in the majority of patients with NAFLD remain unclear.

Obesity 107

Obesity Diet 107

Med Page Today

JUNE 24, 2024

(MedPage Today) -- Metabolic surgery became the first therapy associated with a reduction in incident cardiovascular disease and death among patients with obesity and obstructive sleep apnea (OSA), based on a retrospective cohort study. Such patients.

Obesity 81

Obesity Cardiovascular Disease 81

American Heart News - Heart News

JANUARY 17, 2024

Research Highlights: Consistently high scores of perceived stress during adolescence through adulthood may contribute to worse cardiometabolic health including obesity in young adults. Researchers suggest the adoption of healthy coping strategies.

Obesity 115

Obesity Blood Pressure Diabetes Research 115

HCPLive

AUGUST 6, 2024

This research compared the efficacy among a cohort of individuals with obesity to the general population of adult patients with eczema.

Obesity 59

Obesity Research 59

HCPLive

JUNE 21, 2024

Atul Malhotra, MD, discusses the results of the SURMOUNT-OSA trial and how they inform clinicians on the role of tirzepatide in OSA and obesity.

Obesity 75

Obesity 75

HCPLive

AUGUST 23, 2024

A new study revealed children who go from normal weight to overweight have a greater risk of atopic dermatitis than obese children who maintain their weight.

Obesity 52

Obesity 52

HCPLive

AUGUST 13, 2024

Announced by Rivus Pharmaceuticals, HU6 met its primary endpoint of weight reduction in patients with obesity-related HFpEF in a Phase 2a trial.

Obesity 59

Obesity 59

American College of Cardiology

AUGUST 26, 2024

The goal of the STEP-HFpEF trial was to compare the safety and efficacy of semaglutide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 53

Preserved Ejection Fraction Obesity Heart Failure Article 53

Medical Xpress - Cardiology

JANUARY 16, 2024

Obesity-induced heart disease, which affects up to 10% of the population in certain age ranges, is considered an untreatable condition and 75% of people don't survive more than five years beyond diagnosis.

Obesity 91

Obesity Heart Disease Research 91

American College of Cardiology

JULY 16, 2024

For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), what is the effect of semaglutide on change in New York Heart Association (NYHA) functional class over time?

Preserved Ejection Fraction 57

Preserved Ejection Fraction Obesity Heart Failure Article 57

Science Daily - Heart Disease

JANUARY 17, 2024

Young adults who reported higher stress as adolescents were more likely to have high blood pressure, obesity and other cardiometabolic risk factors as adults, finds new study.

Blood Pressure 97

Blood Pressure Obesity Risk Factors Diabetes 97

Cardiovascular Diabetology

APRIL 1, 2024

Obesity is often associated with multiple comorbidities. However, whether obese subjects with hyperlipidemia in the absence of other complications have worse cardiac indices than metabolically healthy obese su.

Obesity 84

Obesity Research 84

CardiacWire

DECEMBER 6, 2023

The already massive GLP-1 obesity drug segment might have gained a major future competitor last week, following Roche’s acquisition of weight loss biotech Carmot Therapeutics. The biotech also has a once-daily dual GLP-1/GIP injectable (yes, daily) that’s in Phase 2 trials and would treat obese or overweight patients with type 1 diabetes.

Obesity 59

Obesity Diabetes 59